- Home
- DXYZ vs PSNL Comparison
DXYZ vs PSNL Comparison
Compare DXYZ & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- PSNL
- Stock Information
- Founded
- DXYZ N/A
- PSNL 2011
- Country
- DXYZ
- PSNL United States
- Employees
- DXYZ N/A
- PSNL N/A
- Industry
- DXYZ
- PSNL Medical Specialities
- Sector
- DXYZ
- PSNL Health Care
- Exchange
- DXYZ Nasdaq
- PSNL Nasdaq
- Market Cap
- DXYZ 350.2M
- PSNL 321.1M
- IPO Year
- DXYZ 2024
- PSNL 2019
- Fundamental
- Price
- DXYZ $32.26
- PSNL $3.89
- Analyst Decision
- DXYZ
- PSNL Strong Buy
- Analyst Count
- DXYZ 0
- PSNL 4
- Target Price
- DXYZ N/A
- PSNL $6.81
- AVG Volume (30 Days)
- DXYZ N/A
- PSNL 845.3K
- Earning Date
- DXYZ N/A
- PSNL 11-06-2024
- Dividend Yield
- DXYZ N/A
- PSNL N/A
- EPS Growth
- DXYZ N/A
- PSNL N/A
- EPS
- DXYZ N/A
- PSNL N/A
- Revenue
- DXYZ N/A
- PSNL $87,489,000.00
- Revenue This Year
- DXYZ N/A
- PSNL $14.85
- Revenue Next Year
- DXYZ N/A
- PSNL $4.19
- P/E Ratio
- DXYZ N/A
- PSNL N/A
- Revenue Growth
- DXYZ N/A
- PSNL 24.05
- 52 Week Low
- DXYZ N/A
- PSNL $1.02
- 52 Week High
- DXYZ N/A
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- DXYZ N/A
- PSNL 37.60
- Support Level
- DXYZ N/A
- PSNL $4.15
- Resistance Level
- DXYZ N/A
- PSNL $5.40
- Average True Range (ATR)
- DXYZ 0.00
- PSNL 0.50
- MACD
- DXYZ 0.00
- PSNL -0.10
- Stochastic Oscillator
- DXYZ 0.00
- PSNL 3.02
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.